These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19375132)

  • 1. Adherence to Mediterranean diet is favorably associated with metabolic parameters in HIV-positive patients with the highly active antiretroviral therapy-induced metabolic syndrome and lipodystrophy.
    Tsiodras S; Poulia KA; Yannakoulia M; Chimienti SN; Wadhwa S; Karchmer AW; Mantzoros CS
    Metabolism; 2009 Jun; 58(6):854-9. PubMed ID: 19375132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition, visceral fat, lipid, glucose and adipokine metabolism.
    Samaras K; Wand H; Law M; Emery S; Cooper DA; Carr A
    Curr HIV Res; 2009 Jul; 7(4):454-61. PubMed ID: 19601783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome.
    Barbaro G
    Curr Pharm Des; 2007; 13(21):2208-13. PubMed ID: 17627554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does race protect an oriental population from developing lipodystrophy in HIV-infected individuals on HAART?
    Chang KH; Kim JM; Song YG; Hong SK; Lee HC; Lim SK
    J Infect; 2002 Jan; 44(1):33-8. PubMed ID: 11972416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating resistin levels are not associated with fat redistribution, insulin resistance, or metabolic profile in patients with the highly active antiretroviral therapy-induced metabolic syndrome.
    Barb D; Wadhwa SG; Kratzsch J; Gavrila A; Chan JL; Williams CJ; Karchmer AW; Mantzoros CS
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5324-8. PubMed ID: 15956078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy.
    Addy CL; Gavrila A; Tsiodras S; Brodovicz K; Karchmer AW; Mantzoros CS
    J Clin Endocrinol Metab; 2003 Feb; 88(2):627-36. PubMed ID: 12574192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhood.
    Dimock D; Thomas V; Cushing A; Purdy JB; Worrell C; Kopp JB; Hazra R; Hadigan C
    Metabolism; 2011 Jun; 60(6):874-80. PubMed ID: 20947103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy.
    Duong M; Petit JM; Piroth L; Grappin M; Buisson M; Chavanet P; Hillon P; Portier H
    J Acquir Immune Defic Syndr; 2001 Jul; 27(3):245-50. PubMed ID: 11464143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adipokines and highly active antiretroviral therapy related lipodystrophy: clinical study of 52 cases].
    Tao MM; Zhang L; Qiu ZF; Xie J; Han Y; Yu W; Li M; Li TS
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):867-71. PubMed ID: 19671283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.
    Lee JH; Chan JL; Sourlas E; Raptopoulos V; Mantzoros CS
    J Clin Endocrinol Metab; 2006 Jul; 91(7):2605-11. PubMed ID: 16636130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy.
    Hatano H; Miller KD; Yoder CP; Yanovski JA; Sebring NG; Jones EC; Davey RT
    AIDS; 2000 Sep; 14(13):1935-42. PubMed ID: 10997397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum retinol-binding protein 4 correlates with obesity, insulin resistance, and dyslipidemia in HIV-infected subjects receiving highly active antiretroviral therapy.
    Han SH; Chin BS; Lee HS; Jeong SJ; Choi HK; Kim CO; Choi JY; Song YG; Lee HC; Kim JM
    Metabolism; 2009 Nov; 58(11):1523-9. PubMed ID: 19501863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy.
    Sutinen J; Korsheninnikova E; Funahashi T; Matsuzawa Y; Nyman T; Yki-Järvinen H
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1907-10. PubMed ID: 12679491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelial markers and HIV infection in the era of highly active antiretroviral treatment.
    de Larrañaga GF; Bocassi AR; Puga LM; Alonso BS; Benetucci JA
    Thromb Res; 2003 May; 110(2-3):93-8. PubMed ID: 12893023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic syndrome associated with HIV and highly active antiretroviral therapy.
    Barbaro G; Iacobellis G
    Curr Diab Rep; 2009 Feb; 9(1):37-42. PubMed ID: 19192423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome.
    Kosmiski LA; Kuritzkes DR; Lichtenstein KA; Glueck DH; Gourley PJ; Stamm ER; Scherzinger AL; Eckel RH
    AIDS; 2001 Oct; 15(15):1993-2000. PubMed ID: 11600828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral therapy.
    Estrada V; Serrano-Ríos M; Martínez Larrad MT; Villar NG; González López A; Téllez MJ; Fernández C
    J Acquir Immune Defic Syndr; 2002 Jan; 29(1):32-40. PubMed ID: 11782587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
    Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
    AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.